Praveen Tipirneni, Morphic Therapeutic CEO
July 8, 2024 07:19 AM EDTUpdated 09:25 AM
Deals
Pharma

Lil­ly dis­clos­es its first biotech ac­qui­si­tion of the year, buy­ing Mor­phic for $3.2B

Kyle LaHucik

Senior Reporter

Eli Lil­ly said Mon­day it plans to pay $3.2 bil­lion in cash for Mor­phic Ther­a­peu­tic, a biotech work­ing on oral in­te­grin …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

FDA says Ozem­pic, We­govy short­age is over

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times